• About Studies
• Video Library

Welcome to Pharmatech Oncology. Below, you will find a clinical study or a list of clinical studies for your primary indication. Please click "Click For Details" to learn about the clinical study and to see if it may be an option for you. Additionally, you may enter your location below to find the closest study center where clinical trials are currently being conducted. If you have any questions, please contact us toll-free at 1-800-383-6610.

Lymphoma, Peripheral T-Cell

Study Opportunity

Title: Belinostat® for Adult Patients with Peripheral T-Cell Lymphoma

Overview: This study provides Belinostat® to patients whose cancer has resurfaced or not responded to prior treatments. All eligible patients will receive Belinostat® on days 1 through 5 of each 21-day cycle as long as needed, although treatment will be stopped if a patient's cancer gets worse or the patient withdraws from the study. Scans to measure response to treatment are ordered according to standard of care, every 6 weeks.

Study Value: Belinostat® is in a new class of cancer drug called an HDAC-inhibitor which causes cancer cells to die. It also has little or no bone marrow toxicity which enables patients to more often receive the full dose throughout the trial.